Bryan Anderson v. Magellan Health, Inc.

Court of Chancery of Delaware·Decided July 6, 2023·No. C.A. No. 2021-0202-KSJM·Published

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

BRYAN ANDERSON, )

)

Plaintiff, )

)

v. ) C.A. No. 2021-0202-KSJM )

MAGELLAN HEALTH, INC., STEVEN ) J. SHULMAN, SWATI ABBOTT, ) CHRISTOPHER J. CHEN, KENNETH J. ) FASOLA, PETER A. FELD, MURAL R. ) JOSEPHSON, G. SCOTT ) MACKENZIE, LESLIE V. NORWAL, ) and GUY P. SANSONE, )

)

Defendants. )

OPINION

Date Submitted: February 17, 2023 Date Decided: July 6, 2023

Ryan M. Ernst, BIELLI & KLAUDER, LLC, Wilmington, Delaware; Michael A. Rogovin, WEISS LAW, Atlanta, Georgia; Counsel for Plaintiff Bryan Anderson.

Paul J. Lockwood, Arthur R. Bookout, SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP, Wilmington, Delaware; Counsel for Defendants Magellan Health, Inc., Steven J. Shulman, Swati Abbott, Christopher J. Chen, Kenneth J. Fasola, Peter A. Feld, Mural R. Josephson, G. Scott MacKenzie, Leslie V. Norwal, and Guy P. Sansone.

Anthony A. Rickey, MARGRAVE LAW LLC, Wilmington, Delaware; Counsel for Amici Curiae Law Professors Sean J. Griffith and Minor Myers.

McCORMICK, C.

The plaintiff filed this stockholder class action challenging the merger agreement dated January 4, 2021, by which Centene Corporation agreed to acquire Magellan Health, Inc. Magellan had conducted a sale process in 2019 separate from the negotiations that led to the Centene deal. As part of the 2019 process, 24 prospective bidders entered confidentiality agreements containing “don’t ask, don’t waive” provisions. In this suit, the plaintiff claimed that the don’t-ask-don’t-waive provisions impeded the process that led to the Centene deal and, because the provisions were not fully described in the proxy, rendered stockholder disclosures materially deficient. Shortly after the plaintiff filed this suit, Magellan issued supplemental disclosures providing further detail on the don’t-ask- don’t-waive provisions. Magellan also waived its rights under three of the four confidentiality agreements in effect at the time of the supplemental disclosures. The plaintiff agreed that these actions mooted his claims and stipulated to dismissal.

On the theory that the supplemental disclosures and waivers were corporate benefits, the plaintiff’s counsel petitioned the court for an award of $1,100,000 in attorneys’ fees and expenses. Magellan argued in opposition that the benefits achieved were nominal, warranting fees in the range of $75,000 to $125,000. Through a short bench ruling delivered on June 6, 2023, the court awarded $75,000 in fees and expenses.

The eye-popping request for $1,100,000 caught the attention of the academic community, and two professors well known to this court served as amici curiae to advocate for reform in this court’s approach to mootness fee petitions. The professors urged that this court issue a written decision to warn other courts applying Delaware law of these

policy dangers, and they made good points. Hence, this decision sets out the reasoning behind the bench ruling. I. FACTUAL BACKGROUND The facts are drawn from the pleadings and the record before the court, which includes the Complaint and exhibits submitted with the parties’ briefing on the fee petition. 1 A. The Merger Agreement Magellan is a managed healthcare provider that focuses on special populations, complete pharmacy benefits, and other specialty healthcare areas. Centene is a publicly traded healthcare company that provides programs and services to uninsured and under- insured people in the United States.

In late 2018, Centene expressed interest in acquiring Magellan, and the companies entered into a confidentiality agreement in January 2019. In March 2019, Magellan’s stock price spiked, and Centene decided not to submit an offer. After Centene stated that it was not interested in a transaction at that time, the Magellan Board of Directors (the “Board”) determined to canvas the market.

During March 2019, Magellan’s financial advisor contacted potential buyers of Magellan or a Magellan business segment. That process generated interest from 34 potential acquirers, 24 of whom entered into confidentiality agreements containing don’t- ask-don’t-waive provisions. Confidentiality agreements executed by potential acquirers as

1 C.A. No. 2021-0202-KSJM, Docket (“Dkt.”) 1 (Compl.); Dkt. 15 (“Ernst Decl.”).

part of an auction process typically contain “standstill” provisions that obligate the acquirer to refrain from taking actions that relate to acquisition or control of the target. A don’t- ask-don’t-waive provision prohibits a potential acquirer from making any public or private requests to waive the standstill restrictions. Each of the confidentiality agreements, including the don’t-ask-don’t-waive provisions, were in effect for two years from the date of signing.

By the end of March 2019, Magellan had received nine indications of interest. None resulted in an offer to acquire Magellan. One party, Molina Healthcare, Inc., expressed interest in acquiring a Magellan subsidiary, Magellan Complete Care (“MCC”). After diligence, Molina entered into an agreement to acquire MCC dated April 30, 2020.

Centene again proposed acquiring Magellan in May 2020 and diligence followed.

On August 9, 2020, Centene stated that it would submit an indication of interest to acquire Magellan for $98 per share—$86 in cash plus a $12-per-share credit for the then-pending sale of MCC. The Board authorized management to continue discussions with Centene in August 2020. In October 2020, Centene submitted a revised offer of $64.50 in cash and $21.50 in a fixed ratio of Centene stock. Centene then raised its offer twice, submitting a best-and-final cash offer of $95 per share on November 1, 2020.

Based on the November 1 proposal, the Board decided to negotiate exclusively with Centene toward a merger agreement. The Board had determined not to conduct a market check after Centene’s August 2020 offer. It reaffirmed its decision after the November 1 proposal, reasoning that the 2019 process supplied sufficient information concerning the interest (or lack of interest) from other potential bidders.

The MCC acquisition closed on December 31, 2020. Magellan and Centene executed the merger agreement on January 4, 2021. At that time, six of the confidentiality agreements from March 2019 remained in effect, and five of those contained don’t-ask- don’t-waive provisions.

Magellan scheduled a stockholder vote to approve the acquisition for March 31, 2021, and issued a proxy statement (the “Proxy”) on February 19, 2021.

B. This Litigation Plaintiff Bryan Anderson owns stock in Magellan. On March 9, 2021, he filed this lawsuit, moved for expedited proceedings, and sought to enjoin the stockholder vote and merger. He alleged that the remaining five confidentiality agreements containing don’t- ask-don’t-waive provisions tainted the sale process. One of the five of those confidentiality agreements expired two days later, on March 11. Anderson’s motion for a preliminary injunction was slightly over a single page and was never prosecuted or briefed.

C. Defendants Moot This Litigation.

Ten days after filing suit and without discovery, on March 19, 2021, Anderson agreed to dismiss his lawsuit as moot in exchange for Magellan waiving some of the remaining don’t-ask-don’t-waive provisions and issuing supplemental disclosures. Specifically, Magellan agreed to waive the don’t-ask-don’t-waive provisions in confidentiality agreements with three anonymous companies, Companies A, B, and C (the “Waivers”). The fourth remaining agreement was with Molina, and the Board determined

that maintaining the agreement was in Magellan’s best interest. 2 The supplemental disclosures (the “Supplemental Disclosures”), which Anderson’s counsel reviewed and approved, advised stockholders about the history and terms of the don’t-ask-don’t-waive provisions, the purpose of those provisions, and the Waivers.

On March 19, 2021, Magellan published the Supplemental Disclosures in a Form 8-

K filed with the SEC. No other bidder emerged. Magellan stockholders approved the merger on March 31, 2021.

Free access — add to your briefcase to read the full text and ask questions with AI

Bryan Anderson v. Magellan Health, Inc., (Del. Ct. App. 2023).

Bryan Anderson v. Magellan Health, Inc. (Bryan Anderson v. Magellan Health, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United Vanguard Fund, Inc. v. TakeCare, Inc.
693 A.2d 1076 (Supreme Court of Delaware, 1997)
Turner v. Bernstein
768 A.2d 24 (Court of Chancery of Delaware, 2000)
Weinberger v. UOP, Inc.
517 A.2d 653 (Court of Chancery of Delaware, 1986)
Allied Artists Pictures Corp. v. Baron
413 A.2d 876 (Supreme Court of Delaware, 1980)
Sugarland Industries, Inc. v. Thomas
420 A.2d 142 (Supreme Court of Delaware, 1980)
Goodrich v. E.F. Hutton Group, Inc.
681 A.2d 1039 (Supreme Court of Delaware, 1996)
Stroud v. Grace
606 A.2d 75 (Supreme Court of Delaware, 1992)
Chrysler Corporation v. Dann
223 A.2d 384 (Supreme Court of Delaware, 1966)
In Re Cox Communications, Inc. Shareholders Litigation
879 A.2d 604 (Court of Chancery of Delaware, 2005)
C & J Energy Services, Inc. v. City of Miami General Employees'
107 A.3d 1049 (Supreme Court of Delaware, 2014)
In re Activision Blizzard, Inc. Stockholder Litigation
124 A.3d 1025 (Court of Chancery of Delaware, 2015)
Corwin v. KKR Financial Holdings LLC
125 A.3d 304 (Supreme Court of Delaware, 2015)
In re Trulia, Inc. Stockholder Litigation
129 A.3d 884 (Court of Chancery of Delaware, 2016)
Morrison v. Berry
191 A.3d 268 (Supreme Court of Delaware, 2018)
Olenik v. Lodzinski
208 A.3d 704 (Supreme Court of Delaware, 2019)
Emak Worldwide, Inc. v. Kurz
50 A.3d 429 (Supreme Court of Delaware, 2012)
Americas Mining Corp. v. Theriault
51 A.3d 1213 (Supreme Court of Delaware, 2012)
BVF Partners L.P. v. New Orleans Employees' Retirement System
59 A.3d 418 (Supreme Court of Delaware, 2012)
In re Sauer-Danfoss Inc. Shareholders Litigation
65 A.3d 1116 (Court of Chancery of Delaware, 2011)
Kahn v. M & F Worldwide Corp.
88 A.3d 635 (Supreme Court of Delaware, 2014)